Information Provided By:
Fly News Breaks for November 12, 2019
CTVA, AMGN, BIIB, BMRN, STOK, CCC, ARLO
Nov 12, 2019 | 10:16 EDT
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Arlo Technologies (ARLO) resumed with a Buy at Deutsche Bank. 2. Clarivate Analytics (CCC) initiated with a Hold at Stifel. 3. Stoke Therapeutics (STOK) initiated with a Buy at BTIG. 4. BioMarin (BMRN), Biogen (BIIB), and Amgen (AMGN) were initiated with a Buy at SunTrust. 5. Corteva (CTVA) initiated with a Buy at Redburn. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
News For ARLO;CCC;STOK;BMRN;BIIB;AMGN;CTVA From the Last 2 Days
BIIB
Jan 20, 2022 | 06:31 EST
Barclays analyst Carter Gould lowered the firm's price target on Biogen to $244 from $280 and keeps an Equal Weight rating on the shares ahead of the company's Q4 results. Large-cap biotech is "at a crossroads ahead of near-term catalysts," Gould tells investors in a research note.
AMGN
Jan 20, 2022 | 05:09 EST
Amgen announced that Lumakras has been approved in Japan for the treatment of KRAS G12C-mutated positive, unresectable, advanced and/or recurrent non-small cell lung cancer, or NSCLC, that has progressed after systemic anticancer therapy.
BIIB
Jan 19, 2022 | 13:59 EST
Sangamo Therapeutics (SGMO) is a clinical-stage biopharmaceutical company pursuing programs across the spectrum of genomic medicine. In an exclusive interview with The Fly, CEO Sandy Macrae talked about the company's preclinical studies: "Everything is moving forward beautifully. Until we get to the IND, we tend to keep the cards close to our chest on the benefits of our programs. But related to the TX200, which is the renal transplant subject, we have TREG programs being developed in multiple sclerosis for example. In our CNS portfolio, we have very interesting assets in important neurological diseases moving forward and closer to clinic. We will publish results on them during the year. It takes time. We're an unusual company with such a broad and deep portfolio, and a pipeline that keeps on giving and it's all due to our technology which can be applied to so many areas of unmet medical need. And we also have our partnerships with Biogen [BIIB] for Alzheimer's and Parkinson's disease, which is making great progress; our work we are doing with Novartis [NVS] on Autism spectrum disorder, which again is moving forward; with Takeda [TAK] for Huntington's; and with Kite [GILD] and their oncology program. They are all moving forward and getting closer and closer to the IND, which is when investors and analysts really start getting interested in it," the executive explained. "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.
BMRN
Jan 19, 2022 | 13:51 EST
Sangamo Therapeutics (SGMO) is a clinical-stage biopharmaceutical company pursuing programs across the spectrum of genomic medicine. In an exclusive interview with The Fly, COO Mark McClung discussed the company's upcoming data readouts: "We think we have three really important catalysts coming up over the course of the next 12 months. The first is related to our partner program with Pfizer [PFE], which is the Hemophilia A program and is in Phase 3. We're anticipating that the clinical hold put on by Pfizer and the agency will be lifted shortly and we will continue to advance the enrollment in that trial. At this point, we're still confident we will have a competitive profile versus the BioMarin [BMRN] product. The second would be our Fabry disease program. We shared the promising preliminary proof of concept Phase 1/2 data from the first two dosing cohorts back at our Q3 results but since then we've dosed a fifth patient in the high dose third cohort and have line of sight on the six cohort and we've initiated Phase 3 planning. Over the course of 2022, you can expect additional data presentations which will provide the update on the patients. We will most likely share some of that in an upcoming congress. And additionally, there are two sets of information we're hoping to be able to comment on through the end of the year. The first is related to the fact that of the four patients we showed at our Q3 release, two of those patients were on enzyme replacement therapy and for one of those patients - patient four - we already started the withdrawal of the enzyme replacement therapy and we will have the data to see what happens. That patient will still have the benefit of the gene therapy. For the second patient, which was the first patient enrolled in the trial, we're getting consent to do the same thing. Additionally, in the third cohort - so patients 5 and 6 - we've done baseline kidney biopsies and we're hoping that throughout the course of the year, but most likely towards the end of the year, we'll be able to provide a perspective on the impact on the lyso-Gb3 disposition on the kidney. Very excited over that program, particularly in the context of the recent changes in the landscape competitive. We believe that the profile of our Fabry gene therapy program is shaping up very nicely. We're excited about that program which is currently wholly own. Lastly, related to the sickle cell program which has been in the hands of Sanofi [SNY]... Sanofi made a strategic decision as part of its genomics medicine strategy to get out of personalized medicines, including personalized cell therapy - so, we're in the midst of a six-month transition period with them. There are four patients left to dose, which we've committed with Sanofi to complete by the early Q3 of this year. But what's important is these next four patients will be dosed using a new manufacturing. Additionally, the TX200 kidney transplant study with our TX200 compound, which is a CAR-TREG, is the first we believe in human trial with CAR-TREGs. We've enrolled the first patient in the trial and are expecting to dose the first two patients by the middle of 2022," the executive explained. "Meet the Company" is The Fly's recurring series of exclusive short interviews with Executive Officers to offer a deeper look inside the company. The remainder of this interview to follow.